Taysha Gene Therapies, Inc. Gain (Loss) on Extinguishment of Debt
Taysha Gene Therapies, Inc. (TSHA) reported Gain (Loss) on Extinguishment of Debt of -$1.40 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2025-02-26
- Taysha Gene Therapies, Inc. gain (loss) on extinguishment of debt for fiscal 2023 was -$1.40M.
| Period end | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|
| 2023-12-31 | -$1.40M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |